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REVIEW
Abnormal B Cell Development in
Systemic Lupus Erythematosus
What the Genetics Tell Us
Sarah Karrar and Deborah S. Cunninghame Graham
Introduction
Systemic lupus erythematosus (SLE) is an autoim-
mune disease characterized by B cell dysfunction, produc-
tion of autoantibodies directed toward cellular and nuclear
components, and multiorgan damage caused by immune
complex deposition and inflammation within affected
tissues (1). It largely affects women of childbearing age
(the third and fourth decades of life) and is associated with
significant morbidity and mortality.
In healthy individuals, B cells with autoreactive
receptors are selected out during B cell maturation, starting
at the initial stages of B cell receptor (BCR) development
in the bone marrow and continuing through to the fine tun-
ing that occurs in activated mature B cells in secondary
lymphoid tissue. Studies in lupus patients as well as mouse
models indicate that these processes are altered in SLE.
The etiology of the disease is complex and its pheno-
type is highly heterogeneous, but genetic susceptibility is
thought to contribute as much as 60% of disease risk (2).
Although rare monogenic causes do exist, heredity in SLE
is complex, with multiple common variants contributing to
disease, with patients having to achieve a certain “genetic
threshold” for disease risk. This genetic risk, in combination
with environmental factors (exposure to ultraviolet sunlight,
smoking, and infections including Epstein-Barr virus have
all been implicated), leads to development of the disease
(1). In this review, we summarize some of the B cell anoma-
lies in SLE and incorporate evidence from studies in
humans and mouse models, together with data from genetic
association studies, to explain the mechanisms behind B cell
dysregulation in SLE.
The B cell phenotype in SLE
The crucial role of B cells in SLE pathogenesis is
well recognized, from producing autoantibodies to abnor-
mal regulation of immune responses (3,4). Various abnor-
malities have been noted in SLE B cells. First, there is an
imbalance of B cell subtype numbers, with an increase in
class-switched memory B cells relative to naive B cells (3).
Second, B cells from SLE patients have exaggerated BCR
responses, with receptor crosslinking leading to increased
calcium influx and tyrosine phosphorylation of downstream
signaling molecules (3). Increased memory B cell numbers
confer significant disease risk as these have a lower activa-
tion threshold, allowing autoreactive B cells to thrive with
minimal antigen contact, while enhanced receptor activa-
tion contributes to the steady-state active phenotype seen
in SLE (3,5).
B cells contribute to disease mainly by producing
autoantibodies targeting nuclear components including
DNA (anti–double-stranded DNA [anti-dsDNA]), RNP par-
ticles (anti-Ro, anti-La, and anti-Sm), histones, and nonhis-
tone chromatin proteins. These are present in >90% of
patients and contribute to disease progression via immune
complex formation (6). Titers of these autoantibodies (espe-
cially anti-dsDNA) correlate positively with increased disease
activity, and serial measurements are used to monitor
patients for disease flares (6). There is also evidence that
autoantibodies cross-react with cellular components other
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than nuclear targets (7). For example, anti-dsDNA antibod-
ies bind to major glycosaminoglycan components in the
glomerular basement membrane, suggesting a possible
direct role in nephritis (7). In mouse models, transfer of
autoantibodies from diseased to unaffected animals
leads to development of typical immune complex–medi-
ated nephritis (8). Moreover, in MRL/lpr mice (which
develop lupus-like disease spontaneously), disease sever-
ity can be attenuated and mortality reduced by ~50% if
antibody secretion is blocked, providing robust evidence
that autoantibodies are more than spectators in disease
etiology (9).
A recent explosion in genome-wide association
studies (GWAS) has identified >80 potential risk loci across
multiple immunopathologic pathways (10). In this review,
we discuss how genetic variants affect the development of
B cells, allowing them to overcome several checkpoints to
break self tolerance, and how they contribute to the abnor-
mal active phenotype observed in SLE. We examine how
these genes alter both early developmental pathways in the
bone marrow and late maturation processes to cause B cell
dysregulation.
Central tolerance checkpoint of B cell development
in the bone marrow in SLE
Normal B cell development starts in the bone
marrow, where the first round of negative selection of
Figure 1. Central tolerance. 1, Common lymphocyte precursor commits to B cell lineage via expression of B cell–specific transcription factors
(e.g., early B cell factor [EBF]), which initiates IgH rearrangement. 2, Expression of the generated IgH component of the pre–B cell receptor
(pre-BCR) is combined with the surrogate light chain (SLC). 3, Successful signaling through the pre-BCR leads to a short burst of proliferation
and internalization of the pre-BCR and commences a second wave of recombination, this time in the light-chain gene. 4, The generated BCR is
then assessed for self-recognition. Those cells that have generated non–self-recognizing BCRs with functioning signaling switch off recombination-
activating gene (RAG) expression and become immature B cells. 5, Because V[D]J recombination is a stochastic process, a proportion of pre–B
cells will generate autoreactive BCRs. This is detected by excess BCR signaling due to high-affinity binding within the bone marrow or abundance
of antigen. This leads to continued V[D]J recombination until acceptable BCR is generated or all possible recombination has been exhausted. 6,
Failure to generate a non–self-recognizing BCR leads to apoptosis. 7, In autoimmune disease this process is impaired, potentially by reduced sig-
naling through the developing BCR, which fails to trigger the threshold for apoptosis. Genes or proteins involved at each stage are shown in
dashed boxes. * = genes identified as risk-associated loci in systemic lupus erythematosus (SLE). TLR = Toll-like receptor; MyD88 = myeloid dif-
ferentiation factor 88; IRAK-1 = interleukin-1 receptor–associated kinase 1; Unc-93B = Unc-93 homolog B.
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autoreactive B cells (termed central tolerance) occurs.
This process is summarized in Figure 1. Many potential
abnormalities in central tolerance have been implicated in
SLE, including failure of adequate negative selection of
autoreactive B cells and inadequate receptor editing (steps
6 and 3, respectively, in Figure 1), both of which are criti-
cal steps in maintaining tolerance to self (11).
The molecular mechanisms by which SLE autore-
active B cells evade central tolerance have yet to be fully
elucidated. There are some clues, however, from various
genetic studies (12). Patients with single-gene mutations
resulting in primary immunodeficiencies frequently devel-
op a wide range of autoimmune diseases in addition to
increased susceptibility to infections (12). Their mutations
teach us that central tolerance is largely dependent on
adequate BCR signaling in the bone marrow (12) (steps 2
and 3 in Figure 1). In X-linked agammaglobulinemia, a
defect in the gene for Bruton’s tyrosine kinase (needed for
downstream BCR signaling) results in increased frequency
of autoreactive B cells (12). One possible mechanism is
that binding to self antigen does not induce a strong
enough response in BCR signaling to trigger clonal dele-
tion (12). Conversely, deficiency in Wiscott-Aldrich syn-
drome protein (WASP; a negative regulator of BCR
signaling) results in more stringent central control mecha-
nisms, with WASP-knockout mice showing a much lower
proportion of autoreactive B cells being released from the
bone marrow. Their mature B cells also show abnormal
peripheral tolerance and hyperactive phenotype, possibly
driven by Tcell abnormalities (12).
Outside of single-gene mutations, GWAS have
expanded our knowledge of the molecular basis of B
cell developmental anomalies in SLE (13,14). These
GWAS have identified several SLE susceptibility loci
near genes known to be important for early B cell
development and BCR signaling (see Table 1 for sum-
mary). Variants affecting BCR signaling are discussed
in more detail later in this review (13,14).
In early B cell development, several stages have
been described which are associated with distinct genetic
and molecular events. Two of these genes have been iden-
tified as risk loci and are discussed in the next section.
SLE risk loci and their role in the commitment to
B cell lineage, common lymphoid progenitors,
B lymphocyte precursors, pro–B cells, and pre–B cells
Commitment of the multipotent progenitor cells in
the bone marrow to lymphocyte development depends on
the expression of several transcription factors, including
Ikaros (encoded by IKZF1) and Aiolos (encoded by IKZF3),
among others (13,15) (step 1 in Figure 1). Ikaros in
particular is known to be crucial for early commitment to
B cell lineage. Its exact role in the early multipotent pro-
genitor cells is unknown, although we know that mice
deficient in Ikaros fail to develop any common lympho-
cyte precursors, with arrest of B cell development before
lineage commitment to the B cell–biased lymphoid pro-
genitor (16). Low expression of Ikaros allows generation
of some B cells, but overall numbers remain low and dif-
ferentiation is impaired at all stages (16).
The pre–B cell stage is characterized by the expres-
sion of the pre-BCR, and successful signaling through the
pre-BCR arrests recombination of the IgH chain and the
initiation of expression of the Ig light chains of the final
BCR (17) (step 2 in Figure 1). Ikaros and its closely
related family member Aiolos are both induced on
engagement of the pre-BCR and help terminate signaling
through the pre-BCR (steps 2 and 3 in Figure 1), promote
exit from the cell cycle, and allow rearrangement of the Ig
light-chain genes. Ikaros also induces expression of recom-
bination-activating gene 1 (RAG-1) and RAG-2 and is
required for IgH VH gene recombination, allowing the
pro–B cell to progress to the large pre–B cell stage (18).
Both the Ikaros and Aiolos variants (single-nucleo-
tide polymorphism [SNP] rs4917014, which lies within the
30-untranslated region [30-UTR] of the IKZF1 gene [encod-
ing Ikaros] [P = 2.7 9 10–23], and SNP rs2941509, which
lies within the 50-UTR of the IKZF3 gene [encoding Aio-
los] [P = 3.198 9 106]) have been associated with
increased transcription of their respective genes in whole
blood (13,15) (Table 1). In models of overexpression in
pre–B cell lines, increases in Ikaros and/or Aiolos induce
termination of IgH recombination and stop signaling
through pre-BCRs. However, high levels of expression are
required to induce this process; therefore, it is plausible
that both of these variants are promoting early transition
to the small pre–B cell and may be contributing to the
inadequate receptor editing observed in SLE (11,16,19).
Humans with germline mutations in IKZF1 have
an early block in common lymphocyte precursor devel-
opment, with reduced pro–B cell numbers and normal
pre–B cell numbers (20). Approximately half of the
reported patients also developed autoimmune disease,
including 1 who had SLE, suggesting that dysfunction and
abnormalities of early B cell development can result in
both immunodeficiency and autoimmunity (20).
Checkpoint at B cell maturation in the lymphoid
tissue, from immature B cell to plasma cell and
peripheral tolerance
Many abnormalities in peripheral tolerance have
been identified in SLE, from problems with somatic
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hypermutation to memory B cell dysfunction (see Figure 2
for summary). First, SLE patients show aberrant and raised
RAG expression in peripheral B cells (step 6 in Figure 2),
raising the possibility that some autoreactive B cells arise as
a result of mutation of a “healthy” BCR into one that rec-
ognizes self antigen (21). This hypothesis is supported by
analysis of genetic variation in the Ig produced by autoim-
mune mice, showing that point mutations can render a pre-
viously self-tolerant BCR autoreactive (22). These data
have been replicated in the analysis of anti-dsDNA
antibodies from humans with SLE (23). Second, autoanti-
bodies in SLE often evolve over the duration of the disease,
recognizing different epitopes of their respective antigens
and frequently achieving a higher affinity (23,24). The
raised levels of interleukin-6 (IL-6) seen in the disease may
contribute to this, as IL-6 is a known up-regulator of RAG
gene expression (25).
The other major player in this process of secondary
maturation and in the maintenance of tolerance is the T
cell–B cell interaction (step 5 in Figure 2). This is
Figure 2. Peripheral tolerance. 1, Naive B cells in the marginal zone encounter their relevant antigen as presented by resident antigen-presenting cells
(APCs). 2, Some activated B cells remain outside the germinal center and become short-lived low-affinity antibody-producing cells. 3, Activated B cells
migrate to the germinal center (under influence of CXCL12 produced by bone marrow stromal cells), 4, where they interact with follicular helper Tcells
whose Tcell receptors (TCRs) recognize self antigen. This also involves bidirectional signaling through multiple costimulatory molecules and the B cell
receptor (BCR). 5, At this stage, most B cells undergo a round of somatic hypermutation to achieve affinity maturation. This requires expression of the
RAG genes. Following this, activated B cells can differentiate into 3 potential cell types. 6, Long-lived plasma cells are selected from the pool of B cells with
the highest affinity receptors. They up-regulate expression of CXCR4 and migrate toward their niche (usually in the bone marrow), where they reside and
continue to produce background antibody. 7, Some activated cells terminally differentiate into high-affinity plasma cells, which are responsible for the “sec-
ond wave” of high-affinity antibody after antigen exposure. 8,B cells with low-affinity BCRs are preferentially selected to becomememory B cells. Genes or
proteins involved at each of the regulatory stages are shown in dashed boxes. * = genes identified as risk-associated loci in systemic lupus erythematosus
(SLE). IL-21 = interleukin-21; MHC =major histocompatibility complex; IL-21R = IL-21 receptor; RAG = recombination-activating gene; ICOS = induci-
ble costimulator; BANK-1 = B cell scaffold protein with ankyrin repeats 1; UBE2L3 = ubiquitin-conjugating enzyme E2 L3; BLIMP-1 = B lymphocyte–induced
maturation protein 1; XBP-1 =X-box binding protein 1.
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supported by evidence from single-gene immunodefi-
ciency disorders, mouse models, and GWAS (12,14,26).
Patients with single-gene mutations in CD40, CD40L, and
major histocompatibility complex (MHC) class II develop
a significant proportion of autoreactive B cells, including
those with receptors recognizing nuclear components (in-
cluding antinuclear antibodies [ANAs]) (26). This is
despite their having normal central tolerance processes in
the bone marrow (12,26). In the Sle1 murine model, dis-
ease risk is inherited via a region on chromosome 1, carry-
ing polymorphisms in genes encoding multiple receptors
needed for T cell–B cell interactions (including Slam,
Ly108, Cd84, Cracc, and Ly9) (27). In the germinal cen-
ters (GCs) of these mice, transient short-term contact
between B cells and Tcells allows rare autoreactive B cells
and T cells to “sample” many different cells in the GC,
increasing chances of interaction for positive costimula-
tion (27). Shorter contact times between immune cells are
also known to alter their function (e.g., poorer Treg cell
ability to induce tolerance in target cells due to shorter
contact times) (28). It is possible that shorter Tcell–B cell
contact in the GC may lead to chronic, low-grade activa-
tion, allowing autoreactive B cells to survive due to back-
ground low-quality contact, without receiving adequate
signals to become anergic.
Patients and mice with deficiencies in CD40,
CD40L, and MHC class II who have poor T cell–B cell
interaction overcome lack of B cell stimulation by up-
regulating BAFF, a stimulatory cytokine that promotes B
cell survival and proliferation (26). This has important
consequences for B cell activation and murine models in
which mice that overexpress BAFF develop lupus-like dis-
ease with ANAs and anti-dsDNA (29). These findings
suggest that in the absence of specific and controlled
BCR activation, more generic signals (such as BAFF)
promote indiscriminate B cell activation and survival of
self antigens recognizing B cells and normal foreign anti-
gens recognizing cells equally (29). Variants in loci near or
within OX40L/TNFSF4,MHC class II, and CD80 have all
been implicated as associated with risk of SLE in various
GWAS (13,14,30,31) (Table 1).
The SLE-associated variant rs6590330 in the pro-
moter of the gene ETS1 results in down-regulation of
expression of the transcription factor ETS-1 in whole
blood from humans (30). Studies in transgenic mice that
are both deficient in Ets-1 and express an autoreactive
BCR indicate that while central tolerance is maintained,
deficiency in Ets-1 results in impaired anergic responses
(32). B cells from Ets-1–/– mice produced autoantibodies
despite receiving appropriate “anergy” signals and contin-
ued to secrete them even in the absence of interaction
with cognate antigen (32). Some features of B cell anergy
(such as reduced BCR-mediated tyrosine phosphorylation
and Ca2+ influx) could be induced in deficient cells after
stimulation with high-affinity antigen; however, this could
not switch off autoantibody production (32).
The UBE2L3 gene (which codes for ubiquitin-conju-
gating enzyme E2, also known as UBCH7) on chromosome
22 contains a risk variant (associated SNP rs140490, P =
7.5 9 10–8) within its promoter that leads to increased
expression and protein levels in B cells (but not in other
immune cells such as T cells) (31). UBCH7 drives NF-jB
activation through increased linear ubiquitin chain assembly
complex–mediated ubiquitination and subsequent proteaso-
mal degradation of IjBa, an inhibitor of NF-jB (31).
Raised basal levels of NF-jB led to steady-state activation
and augmented responses to stimulatory signals (31). This
resulted in higher numbers of both plasmablasts and plasma
cells and modulated response to stimulatory signals such as
CD40 and tumor necrosis factor (TNF) (Table 1 and step 5
in Figure 2) in carriers of the risk variant (31).
Variants affecting B cell signaling molecules affect
both peripheral and central tolerance mechanisms
Variants affecting B cell and pre–B cell signaling
affect both central and peripheral tolerance, and many
genes involved in both BCR and pre-BCR signaling have
been identified from GWAS (13,14). These variants con-
tribute to the generation of autoreactive B cells and the
activated phenotype identified in peripheral B cells in SLE
(13,14) (Table 1). Variants resulting in impaired BCR sig-
naling are thought to contribute to autoimmunity in a
mechanism analogous to that noted in the monogenic
immunodeficiencies discussed above, in which inadequate
pre-BCR signaling leads to failure in reaching the thresh-
old for clonal deletion or BCR rearrangement (12,33).
Variants contributing to increased BCR-mediated signaling
may promote the peripheral active B cell phenotype char-
acteristic of SLE (34,35). Risk variants identified in SLE
include PTPN22, Blk, Csk, and Lyn (13,14,36) (step 3 in
Figure 1 and step 4 in Figure 2).
The risk allele (SNP rs476601, P = 3.4 9 10–12)
for PTPN22, which encodes the tyrosine kinase Lyp, is
associated with impaired BCR signaling and is thought
to contribute to autoreactive B cell survival through vari-
ous mechanisms (14) (Table 1). This risk variant is asso-
ciated with faulty central tolerance and failure to remove
autoreactive B cells in the bone marrow (33). In addi-
tion, peripheral B cells carrying this risk allele up-regu-
lated many genes involved in B cell activation, including
those involved in BCR, CD40, and Toll-like receptor
(TLR) signaling as well as cytokine receptors (e.g., IL-21
receptor [IL-21R] and IL-4R) (34). Moreover, these B
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cells show increased surface expression of CD40 as well
as enhanced responses to CD40 engagement, potentially
contributing to the active peripheral phenotype (34).
Up-regulation of these proactivation genes is thought to
be a mechanism by which B cells overcome the deficit in
Lyp function caused by the risk variant (34).
Blk, a Src family tyrosine kinase, is normally up-
regulated at the pre–B cell stage and is important in the
transduction of pre-BCR signaling (37). Blk phosphory-
lates the Ig a- and b-subunits of the BCR and is known to
bind the phosphatidylinositol lipase C-c230, forming a
complex with the B cell adaptor protein ankyrin repeats
(encoded by the BANK1 gene and, interestingly, also a sus-
ceptibility locus for SLE) during BCR signaling (38). The
disease-associated SNPs for Blk (rs922483 and rs1382568)
both result in the down-regulation of Blk expression and
potential failure of adequate pre-BCR signaling (36,39)
(Table 1). A third and rarer coding variant of Blk associ-
ated with SLE that results in an alanine-for-threonine sub-
stitution in its SH3 domain leads to hypophosphorylation,
inactivation, and rapid degradation of the protein (40).
This variant also demonstrates impaired binding to B cell
scaffold protein with ankyrin repeats 1 (BANK-1) scaffold-
ing, which is important in signal transduction (40).
Blk–/– mice develop autoimmune disease, with anti-
dsDNA autoantibodies and immune complex–mediated
glomerulonephritis, together with an increase in the pro-
portion of B-1 cells (a low-affinity IgM-producing subtype
of B cells in mice) (41). Expansion of this subtype of B cells
in other murine models of lupus is well documented and is
thought to be important, particularly in driving nephritis
(41). In a mechanism similar to that of the Lyp variant, this
may contribute to autoimmunity by impairing central toler-
ance mechanisms. However, abnormalities in peripheral
BCR signaling have also been described, with low baseline
BCR activity at rest but enhanced responses on activation,
heightened ability to stimulate T cells, and increased num-
bers of isotype-switched memory B cells (42).
CSK, located on chromosome 15, carries a risk vari-
ant (SNP rs34933034) that up-regulates expression of Csk,
a Src family tyrosine kinase important in the BCR signal-
ing cascade (35). B cells from those carrying the risk allele
show increased levels of Csk expression and increased
subsequent phosphorylation of Lyp, augmented BCR
responses, and activation of mature B cells (35).
Lyn, another member of the Src kinase family, has
also been associated with SLE (36,43). Initial GWAS
identified rs57829816 in the 50 region (P = 5.4 9 10–9) and
rs2667978 in the 30 region (P = 5.1 9 10–8) in women of
European ancestry, with both variants being protective.
Further transancestral case–control studies identified a
third variant in American women of European ancestry,
rs6983130 in the 50-UTR of the gene (P = 0.000111) (36).
This variant was also protective and was associated with
less severe disease within cases (36). No association
between any Lyn variants and disease has been identified
in populations of African or Asian ancestry, nor has there
been any association with changes in protein or transcript
levels (36,43,44). However, data from SLE patients have
shown them to have lower levels of Lyn compared to
healthy controls, implying that lower levels may be associ-
ated with disease (45,46). In addition, studies in B cell
lines show that Lyn is required for inhibitory signals in
response to weak BCR crosslinking (47). Lyn–/– mice are
susceptible to an inducible immune complex–mediated
nephritis as well as to antibody-induced arthritis (47).
Patients deficient in IL-1R–associated kinase 4,
myeloid differentiation factor 88, and Unc-93 homolog B
(signaling molecules in the TLR pathway) also have high
levels of autoreactive B cells, suggesting that impaired sig-
naling via these pathways results in survival of autoreactive
BCRs, possibly by failing to pass the signaling threshold
for clonal deletion in the bone marrow (12) (step 3 in Fig-
ure 1). These patients also demonstrated impaired recep-
tor editing and had defects in peripheral tolerance (48).
SNP rs3853839 in the 30-UTR of TLR-7 (P = 2 9 10–9) has
been associated with SLE in several GWAS (14). This vari-
ant is associated with increased transcript levels and ampli-
fied signaling, resulting in an enhanced interferon (IFN)
signature (14). A study in Danish patients with SLE found
that variants in TLRs 7–9 were associated with certain
disease phenotypes and specific serologic markers (49).
For example, some TLR-7 variants were associated with
nephritis and anti-dsDNA antibodies (49).
Checkpoint at the level of memory cells and long-lived
plasma cells in SLE
Although abnormalities in both central and
peripheral tolerance are pivotal to pathology, memory B
cells and long-lived plasma cells contribute substantially
to disease propagation (50). One of the most striking B
cell findings in SLE is the high prevalence of mature,
antigen-experienced class-switched memory cells (3).
The effect of having a relatively large proportion of these
cells is multifold. First, these cells are primed for action
and have a lower activation threshold compared to naive
B cells. Second, they exhibit resistance to regulatory and
inhibitory signals (3). In addition, SLE patients have a
unique group of memory B cells in the periphery which
lack CD27 expression (a hallmark of memory B cell phe-
notype), the numbers of which correlate with increased
disease activity, renal involvement, and higher serum
levels of autoantibodies (51).
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The endurance of autoreactive long-lived plasma
cells and their resistance to treatments such as B cell
depletion and chemotherapy demonstrate the importance
of this plasma cell subtype in disease persistence. In
lupus-prone mice, long-lived plasma cells develop early
and continue to expand throughout their lifetime (50).
Murine models indicate a prominent role for these long-
lived plasma cells in autoimmunity; for example, anti-
bodies derived from long-lived plasma cells were found
in diseased kidneys of NZB/NZW mice (8). In addition,
these long-lived plasma cells are thought to be responsi-
ble for the production of anti-RNA antibodies, which
explains why the titers of these antibodies are not altered
with B cell depletion therapy (52,53).
Development and survival of long-lived plasma
cells and memory cells is complex and depends on a
functioning GC (54). Within the GC, there is stringent
selection of cells with high-affinity receptors to become
long-lived plasma cells, while memory B cells undergo a
less rigorous selection process (Figure 2) (54). Memory
B cells do acquire increased affinity over time, and some
studies suggest that they may re-enter the follicle and
undergo further maturation. While long-lived plasma
cells reside in “niches” usually within the bone marrow,
memory B cells are found circulating in the periphery
and dwelling in secondary lymphoid tissue (54).
Various GWAS in SLE have identified an associ-
ation with the gene encoding the protein OX40L/TNF
ligand superfamily member 4 (55) (Table 1 and step 5
in Figure 2). This gene codes for a membrane-bound
protein expressed on the surface of memory B cells,
with its unique receptor OX40 primarily expressed on
CD4+ Th cells. The OX40L–OX40 interaction results
in bidirectional signaling in both the B cell and T cell
involved, activation in both cells, and augmentation of
the immune response (55). Although the effect of the
identified variant on OX40L expression has not been
fully identified, we know that both OX40L and OX40
are found at higher levels in patients with SLE, particu-
larly those with more active disease and with a more
severe disease phenotype (as indicated by the pres-
ence of nephritis) (55). These findings suggest that
these proteins contribute to the increased number and
more active phenotype of memory B cells in SLE.
GWAS data sets also show disease association with
many of the genes associated with the development of
immunologic memory including BACH2, PRDM1, and
IKZF3 (13,14,56) (Table 1 and steps 6–8 in Figure 2). The
exact effect of the risk variant in each of these genes on
function is not yet known, but these associations hint that
the proteins may contribute to the dysregulation of the
developmental pathways in memory and long-lived plasma
cells. Of particular interest, we know that mice lacking
Aiolos fail to develop immunologic memory although they
have normal initial responses to antigen exposure and are
at increased risk of developing B cell lymphoma (57).
Aiolos–/– mice also develop a lupus-like disease in old age,
with typical autoantibodies and immune complex deposi-
tion (57). This autoimmune phenotype comes about as a
result of a B cell defect with retention of both relatively
normal Tcells and innate immune system (57).
Two polymorphisms in BANK1 have been identi-
fied as associated with risk (13,14,40,58) (Table 1). Both
impair BCR and CD40 signaling and are associated with
an expansion of memory B cells in vivo (58) (step 4 in Fig-
ure 2). BANK1 encodes a scaffolding protein that acts
during BCR signaling by promoting phosphorylation of
Src tyrosine kinases such as Lyn through enabling pro-
tein–protein interactions between them and inositol 1,4,5-
trisphosphate receptor (59). One of the risk polymor-
phisms (rs10516487) is associated with alternative splicing
which results in a protein that forms larger and more
widespread scaffolds within the cytoplasm (59). The effect
of the other risk variant (rs17266594) on BANK-1 expres-
sion is currently unknown.
Extrinsic factors
Failure of tolerance in SLE is due in large part to
the intrinsic defects discussed above, but it is important to
note that B cells develop in an abnormal milieu in lupus
patients compared to healthy controls. Analysis of bone
marrow aspirates from patients with SLE demonstrates
some interesting findings (60). First, there were more
apoptotic cells within lupus bone marrow, potentially
exposing developing pre–B cells to more nuclear self
antigens and propagating the development of autoreac-
tive BCRs (60). Second, there were increased numbers of
CD4+ T cells, macrophages, and plasma cells, creating a
proinflammatory environment (60). These inflammatory
cells produced significant amounts of IFN (a high level of
the cytokine in the bone marrow was associated with
increased disease activity), which has profound effects on
B cell development (61). An abundance of IFN in bone
marrow leads to arrested development at the early stages
and expansion at the transitional B cell stage (61). Simi-
larly, the lymphoid tissue in SLE is also altered (62). The
GCs are areas with a high proportion of cells undergoing
proliferation and apoptosis. Under normal circumstances,
apoptotic cells are rapidly cleared, but in SLE there are
well-known defects in this process (for extensive review,
see ref. 63) potentially leading to persistence of apoptotic
material including nuclear components and perpetuating
the antigen-driven B cell response (62).
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Although epigenetic annotation of risk variants
identifies the B cell as the main cell of interest for the dis-
ease, risk variants affecting many aspects of the immune
system from innate to adaptive have been described
(14,64–66). Many of the risk loci associated with SLE dis-
cussed in this review also affect genes with multilineage
functions. For example, the IKZF1 variant has also been
shown to affect expression of complement components
and several IFN response genes, while Lyp is required for
Tcell receptor signaling (14,67).
Another good example of this is the variant
affecting PRDM1, which encodes for B lymphocyte–in-
duced maturation protein 1 (BLIMP-1), a transcription
factor crucial for plasma cell differentiation. The effect
of the risk variant rs548324, however, is demonstrable
in dendritic cells (DCs), which show a reduction in
expression as a result of the variant, a reduction not
replicated in B cells (68). BLIMP-1 knockout in DCs is
associated with an increase in IL-6 secretion as well as
increased numbers of follicular T cells and GC B cells,
with female mice developing SLE-like disease (68).
Therefore, while the ultimate phenotypic outcome of a
specific variant may be B cell dysfunction, the actual
molecular abnormality may not be B cell specific.
Summary
Although the immunologic abnormalities in SLE
are complex, numerous, and not fully understood, B cells
have a central role in the development of the disease,
from driving immune complex production to secretion of
proinflammatory cytokines. Since SLE is an archetypal
complex disease, the genetic association data reflect that
complexity, with many variants, affecting several areas of
the immune system (13,14).
The advent of GWAS has identified many poten-
tial abnormal pathways relevant to the breaking of self
tolerance in SLE (summarized in Table 1). The data
emphasize the central role of B cells, with a significant
proportion of identified genes affecting B cell function
and epigenetic annotation reinforcing this (13,14,65,66).
GWAS have also helped to explain clinical variability
between individuals—it is easy to see how each patient is
likely to have a different combination of risk variants
resulting in a pattern of immune dysfunction unique to
that individual. We can already see how variants in TLR
genes can help predict disease and serologic markers, or
how variants in the gene for Lyn can protect against
hematologic involvement (36,49).
Traditionally, B cell–targeted therapy has mostly
been focused on depletion of numbers (e.g., through target-
ing CD20-mediated depletion through rituximab), but with
our growing understanding, less crude approaches are being
investigated. For example, Aiolos depletion therapy with
the CC-220 molecule results in down-regulation of genes
mediating B cell differentiation, reduces proliferation, and
inhibits antibody secretion in B cells from SLE patients
(69). Emerging therapy such as epratuzumab (a monoclonal
antibody to CD22) has been shown to block B cell differen-
tiation and activation directly through selective inhibition of
BLIMP-1 (encoded by PRDM1), demonstrating how data
from GWAS can inform future drug therapy (70).
Although the results from GWAS confirm the
complexity of SLE pathogenesis and show that different
intrinsic B cell abnormalities are likely to drive disease in
each individual case, the principles underlying the loss of
central tolerance (deficient BCR signaling) and periph-
eral tolerance (dysregulated T cell–B cell interaction) are
universal. Genetic information helps us to personalize
therapy, whereby relevant molecules can be targeted
through understanding the exact pathways involved in an
individual’s disease.
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